E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines

Oncotarget

Volumn 6, Issue 27, 2015, Pages 23930-23943

  Li, Liming ^a   Xu, Cui ^a   Long, Jia ^a   Shen, Danbei ^a   Zhou, Wuqing ^a   Zhou, Qiyan ^a   Yang, Jia ^a   Jiang, Mingjun ^a  

^a INSTITUTE OF DERMATOLOGY   (China)

Author keywords

Cell viability and apoptosis; DNA methylation; HPV16 E6 and E7; Human cervical carcinoma cell lines; Immunoblot

Indexed keywords

DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; MESSENGER RNA; OSTEONECTIN; PROTEIN E6; PROTEIN E7; SECRETED FRIZZLED RELATED PROTEIN 1; SHORT HAIRPIN RNA; DNA (CYTOSINE 5) METHYLTRANSFERASE; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CARCINOMA CELL LINE; CASKI CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DNA METHYLATION; DNMT1 GENE; DNMT3A GENE; DNMT3B GENE; DNMT3L GENE; DOWN REGULATION; E6 GENE; E7 GENE; GENE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MT1G GENE; NMES1 GENE; PROTEIN EXPRESSION; RNA SEQUENCE; RRAD GENE; SFRP1 GENE; SIHA CELL LINE; SPARC GENE; TFPI2 GENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIRUS GENE; CARCINOMA; CELL SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN PAPILLOMAVIRUS TYPE 16; LENTIVIRINAE; METABOLISM; PHENOTYPE; TUMOR CELL LINE; UTERINE CERVIX TUMOR;

APOPTOSIS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, VIRAL; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMAN PAPILLOMAVIRUS 16; HUMANS; LENTIVIRUS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PHENOTYPE; REPRESSOR PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; UTERINE CERVICAL NEOPLASMS;

EID: 84943384070     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4525     Document Type: Article

References (61)

1. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65:p. 87-108.
2. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55:p. 74-108.
3. Zhou, J., et al., Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Antiviral Research, 2013. 98:p. 305-313.
4. Rampias, T., et al., E6 and E7 Gene Silencing and Transformed Phenotype of Human Papillomavirus 16-Positive Oropharyngeal Cancer Cells. JNCI Journal of the National Cancer Institute, 2009. 101:p. 412-423.
5. Zhou, J., et al., Transcriptional gene silencing of HPV16 E6/E7 induces growth inhibition via apoptosis in vitro and in vivo. Gynecologic Oncology, 2012. 124:p. 296-302.
6. Fehrmann, F. and L.A. Laimins, Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene, 2003. 22:p. 5201-7.
7. Clifford, G.M., et al., Human papillomavirus types in invasive cervical cancer worldwide:a meta-analysis. Br J Cancer, 2003. 88:p. 63-73.
8. Hong, D., et al., Distribution of human papillomavirus genotypes in the patients with cervical carcinoma and its precursors in Zhejiang Province, China. Int J Gynecol Cancer, 2008. 18:p. 104-9.
9. Zur, H.H., Papillomaviruses and cancer:from basic studies to clinical application. Nat Rev Cancer, 2002. 2:p. 342-50.
10. Elbashir, S.M., et al., Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J, 2001. 20:p. 6877-88.
11. Bitko, V., et al., Inhibition of respiratory viruses by nasally administered siRNA. Nat Med, 2005. 11:p. 50-5.
12. Dasgupta, R. and N. Perrimon, Using RNAi to catch Drosophila genes in a web of interactions:insights into cancer research. Oncogene, 2004. 23:p. 8359-65.
13. Hannon, G.J. and J.J. Rossi, Unlocking the potential of the human genome with RNA interference. Nature, 2004. 431: p. 371-8.
14. Capodici, J., K. Kariko and D. Weissman, Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J Immunol, 2002. 169:p. 5196-201.
15. Jacque, J.M., K. Triques and M. Stevenson, Modulation of HIV-1 replication by RNA interference. Nature, 2002. 418: p. 435-8.
16. ter Brake, O., et al., Silencing of HIV-1 with RNA interference:a multiple shRNA approach. Mol Ther, 2006. 14:p. 883-92.
17. Anderson, J. and R. Akkina, CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection. Retrovirology, 2005. 2:p. 53.
18. ter Brake, O., et al., Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther, 2008. 16:p. 557-64.
19. Henry, S.D., et al., Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol Ther, 2006. 14:p. 485-93.
20. Wu, K.L., et al., Inhibition of Hepatitis B virus gene expression by single and dual small interfering RNA treatment. Virus Res, 2005. 112:p. 100-7.
21. Jiang, M. and J. Milner, Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene, 2002. 21:p. 6041-8.
22. Butz, K., et al., siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene, 2003. 22:p. 5938-45.
23. Putral, L.N., et al., RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol, 2005. 68: p. 1311-9.
24. Gu, W., et al., Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther, 2006. 13:p. 1023-32.
25. Yoshinouchi, M., et al., In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol Ther, 2003. 8:p. 762-8.
26. Fujii, T., et al., Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol, 2006. 29:p. 541-8.
27. Jonson, A.L., et al., Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer. Gynecol Oncol, 2008. 111:p. 356-64.
28. Laird, P.W., The power and the promise of DNA methylation markers. Nat Rev Cancer, 2003. 3:p. 253-66.
29. Levenson, V.V., Biomarkers for early detection of breast cancer:what, when, and where? Biochim Biophys Acta, 2007. 1770:p. 847-56.
30. Sova, P., et al., Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev, 2006. 15:p. 114-23.
31. Wojdacz, T.K. and A. Dobrovic, Methylation-sensitive high resolution melting (MS-HRM):a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res, 2007. 35:p. e41.
32. Candiloro, I.L.M., T. Mikeska and A. Dobrovic, Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics, 2014. 6:p. 500-507.
33. Kristensen, L.S., et al., Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM. BMC Cancer, 2009. 9:p. 453.
34. Burgers, W.A., et al., Viral oncoproteins target the DNA methyltransferases. Oncogene, 2006. 26:p. 1650-1655.
35. Leonard, S.M., et al., Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis, 2012. 33:p. 1286-1293.
36. Au, Y.C., et al., HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol Rep, 2010. 24:p. 1599-604.
37. Jurkowska, R.Z., T.P. Jurkowski and A. Jeltsch, Structure and function of mammalian DNA methyltransferases. Chembiochem, 2011. 12:p. 206-22.
38. Vossen, R.H., et al., High-resolution melting analysis (HRMA):more than just sequence variant screening. Hum Mutat, 2009. 30:p. 860-6.
39. Levine, B.L., et al., Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A, 2006. 103:p. 17372-7.
40. Manilla, P., et al., Regulatory considerations for novel gene therapy products:a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther, 2005. 16:p. 17-25.
41. Kristensen, L.S. and L.L. Hansen, PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem, 2009. 55:p. 1471-83.
42. Herman, J.G., et al., Methylation-specific PCR:a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A, 1996. 93:p. 9821-6.
43. Cameron, E.E., S.B. Baylin and J.G. Herman, p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood, 1999. 94:p. 2445-51.
44. Kristensen, L.S., et al., Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP):highthroughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res, 2008. 36:p. e42.
45. Rand, K., et al., Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods, 2002. 27:p. 114-20.
46. Shaw, R.J., et al., Methylation enrichment pyrosequencing: combining the specificity of MSP with validation by pyrosequencing. Nucleic Acids Res, 2006. 34:p. e78.
47. Eads, C.A., et al., MethyLight:a high-throughput assay to measure DNA methylation. Nucleic acids research, 2000. 28:p. E32.
48. Tserga, A., Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncology Reports, 2011.
49. Evan, G.I. and K.H. Vousden, Proliferation, cell cycle and apoptosis in cancer. Nature, 2001. 411:p. 342-8.
50. Ting, A.H., et al., Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet, 2005. 37:p. 906-10.
51. Zhou, J., et al., Inhibition of cervical cancer cell growth in vitro and in vivo by lentiviral-vector mediated shRNA targeting the common promoter of HPV16 E6 and E7 oncogenes. Antiviral Res, 2013. 98:p. 305-13.
52. Taxman, D.J., et al., Criteria for effective design, construction, and gene knockdown by shRNA vectors. BMC Biotechnol, 2006. 6:p. 7.
53. Hong, D., et al., Gene silencing of HPV16 E6 E7 induced by promoter-targeting siRNA in SiHa cells. British Journal of Cancer, 2009. 101:p. 1798-1804.
54. Bousarghin, L., et al., Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAs. Molecular Cancer Therapeutics, 2009. 8:p. 357-365.
55. Li, L., et al., Multiple promoters and targeted microRNAs direct the expressions of. Animal Genetics, 2013. 44(3):p. 241-250.
56. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25:p. 402-8.
57. Bougel, S., et al., Methylation of the hTERT Promoter: A Novel Cancer Biomarker for Leptomeningeal Metastasis Detection in Cerebrospinal Fluids. Clinical Cancer Research, 2013. 19:p. 2216-2223.
58. Migheli, F., et al., Comparison study of MS-HRM and pyrosequencing techniques for quantification of APC and CDKN2A gene methylation. PLoS One, 2013. 8:p. e52501.
59. Xiao, Z., et al., Validation of methylation-sensitive highresolution melting (MS-HRM) for the detection of stool DNA methylation in colorectal neoplasms. Clinica Chimica Acta, 2014. 431:p. 154-163.
60. Butz, K., et al., Functional p53 protein in human papillomavirus-positive cancer cells. Oncogene, 1995. 10: p. 927-36.
61. Butz, K., et al., siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene, 2003. 22:p. 5938-45.